Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha1-antitrypsin deficiency: A randomized study

BMC Clinical Pharmacology

Volumn 10, Issue , 2010, Pages

  Stocks, James M ^a   Brantly, Mark L ^b   Wang Smith, Laurene ^c   Campos, Michael A ^d   Chapman, Kenneth R ^e   Kueppers, Friedrich ^f   Sandhaus, Robert A ^g   Strange, Charlie ^h   Turino, Gerard ⁱ  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c INDAPharma LLC   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f TEMPLE UNIVERSITY HOSPITAL   (United States)

^g DEPARTMENT OF MEDICINE   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTINEOPLASTIC AGENT; ETOPOSIDE; MITOXANTRONE; PREDNISONE; PROTEINASE INHIBITOR; VINCRISTINE;

ADULT; ALPHA 1 ANTITRYPSIN DEFICIENCY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MULTICENTER STUDY; PARVOVIRUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALNUTRITION; METABOLISM;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; ETOPOSIDE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MALNUTRITION; MITOXANTRONE; PREDNISONE; PROTEASE INHIBITORS; VINCRISTINE;

EID: 77957201481     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-10-13     Document Type: Article

References (16)

1. de Serres FJ. Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environ Health Perspect 2003, 111:1851-1854. 10.1289/ehp.6511, 1241756, 14654440.
2. Kohnlein T, Welte T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am J Med 2008, 121:3-9. 10.1016/j.amjmed.2007.07.025, 18187064.
3. Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008, 3:16-24. 10.1186/1750-1172-3-16, 2441617, 18565211.
4. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003, 168:818-900. 10.1164/rccm.168.7.818, 14522813.
5. The Alpha-1-Antitrypsin Deficiency Registry Study Group: Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am J Respir Crit Care Med 1998, 158:49-59.
6. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with α1-protease inhibitor deficiency before and during therapy with IV α1-protease inhibitor. Chest 2001, 119:737-744. 10.1378/chest.119.3.737, 11243951.
7. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha 1 antitrypsin deficiency: a meta-analysis. COPD 2009, 6:177-184. 10.1080/15412550902905961, 19811373.
8. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998, 11:428-433. 10.1183/09031936.98.11020428, 9551749.
9. Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus R, Crystal RG. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003, 123:1425-1434. 10.1378/chest.123.5.1425, 12740257.
10. Bernhardt T, Cortes R. Post license safety of prolastin. Eur Respir J 2006, 28(Suppl 50):518s.
11. Pifat D, Osheroff W, Hotta J, Roth N, Cai K, Petteway S. Pathogen safety of Prolastin®. Eur Respir J 2006, 28(Suppl 50):518s.
12. Burdick MD, Pifat DY, Petteway SR, Cai K. Clearance of prions during plasma protein manufacture. Transfus Med Rev 2006, 20:57-62. 10.1016/j.tmrv.2005.08.005, 16373188.
13. Zimmerman TP. Yield improvement for manufacture of alpha-proteinase inhibitor. Vox Sang 2006, 91:309-315. 10.1111/j.1423-0410.2006.00841.x, 17105606.
14. Cai K, Gierman TM, Hotta J, Stenland CJ, Lee DC, Pifat DY, Petteway SR. Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens. BioDrugs 2005, 19:79-96. 10.2165/00063030-200519020-00002, 15807628.
15. Beatty K, Bieth J, Travis J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem 1980, 255:3931-3934.
16. US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER). 2001, Guidance for Industry: Statistical Approaches to Establishing Bioequivalence, Accessed May 2010., http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070244.pdf